Stockscreener 앱 받기
18.12
0.82%
-0.15
시간 외 거래:
18.22
0.10
+0.55%
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris Inc Agencies, 2026 - OpenSecrets
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris sues Novo Nordisk, seeks to market generic Wegovy - Seeking Alpha
Viatris sues Novo Nordisk over generic Wegovy patent dispute - Yahoo Finance
Viatris sues Novo Nordisk over generic Wegovy patent dispute By Investing.com - Investing.com Canada
Mylan asks US court to clear Wegovy generic from Novo patent claims - Reuters
Trump seeks to produce more generic drugs in the US - Seeking Alpha
Viatris (VTRS) Q1 2026 Earnings Call Transcript - fortune.com
Is Viatris Stock Outperforming the S&P 500? - Yahoo Finance
How Viatris Inc. (VTRS) Affects Rotational Strategy Timing - Stock Traders Daily
Viatris (VTRS) Q4 2025 Earnings Call Transcript - fortune.com
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says - marketscreener.com
Oppenheimer Initiates Viatris at Outperform With $25 Price Target - marketscreener.com
Oppenheimer initiates Viatris stock with outperform rating - Investing.com
Oppenheimer initiates Viatris stock with outperform rating By Investing.com - Investing.com Nigeria
Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic Collaborations - DirectorsTalk Interviews
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? - Yahoo Finance
Viatris (VTRS) Q2 2026 Earnings Call Transcript - fortune.com
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Piper Sandler raises Viatris stock price target on patch growth - Investing.com
Viatris receives Japan approval for sleep disorder drug Wakix - Investing.com
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome - PR Newswire
Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating - Yahoo Finance
Japan approves a first-of-its-kind treatment for narcolepsy and sleep apnea - Stock Titan
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards? - Eastern Progress
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - Yahoo Finance
Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus
Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.36% Potential Upside Amidst Mixed Financial Signals - DirectorsTalk Interviews
Viatris' China Policy Concerns Overstated, UBS Says - Moomoo
Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Healthcare Giant with a 13.99% Upside and Strategic Collaborations - DirectorsTalk Interviews
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance
Viatris Inc (VTRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
0.84%
0.71%
자본화:
|
볼륨(24시간):